Cancers · 2023 · 11 citations · 22 references
MedicinePharmacologyPharmacotherapyGastrointestinal OncologyHepatic PharmacotherapyOncology PharmacotherapyCirrhosisCirrhosis PharmacotherapyHepatocellular CarcinomaHepatocellular Carcinoma PharmacotherapyLiver DiseaseBleeding HistoryCirrhosis-associated CarcinomaLiver Cancer EpidemiologyLiver Disease Risk AssessmentMortality RatesOverall MortalityPrognosis In CirrhosisPropensity Score Adjustment
BACKGROUND: Cirrhosis is the primary risk factor for hepatocellular carcinoma (HCC) and gastrointestinal bleeding (GI). We aimed to assess the efficacy and safety of daily aspirin on HCC occurrence, overall survival, and GI bleeding in cirrhotic patients. METHODS: A total of 35,898 eligible cases were enrolled for analyses from an initial 40,603 cirrhotic patients without tumor history. Patients continuously treated with aspirin for at least 84 days were in the therapy group, whereas those without treatment were controls. A 1:2 propensity score matching by age, sex, comorbidities, drugs, and significant clinical laboratory tests with covariate assessment was used. RESULTS: = 0.0072) inversely correlated with the treatment duration [3-12 months: HR 0.88 (95% CI 0.58-1.34); 12-36 months: HR 0.56 (0.31-0.99); and ≥ 36 months: HR 0.37 (0.18-0.76)]. Overall mortality rates were significantly lower among aspirin users compared with untreated controls [three-year HR 0.43 (0.33-0.57); five-year HR 0.51 (0.42-0.63)]. Consistent results were obtained when the laboratory data were included in the propensity score for matching. CONCLUSIONS: Long-term aspirin use significantly reduced the incidence of HCC and overall mortality without increasing gastrointestinal bleeding in cirrhotic patients.
22
Sadaf G Sepanlou, Saeid Safiri, Catherine Bisignano et al. · The Lancet. Gastroenterology & hepatology · 2020 · 1.7K citations · Full text
Paraneoplastic Thrombocytosis in Ovarian Cancer
Rebecca L. Stone, Alpa M. Nick, Iain A. McNeish et al. · New England Journal of Medicine · 2012 · 822 citations · Full text
Medicine, Hematology, Oncology +13
Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease
Fasiha Kanwal, Jennifer R. Kramer, Srikar Mapakshi et al. · Gastroenterology · 2018 · 783 citations